Cancer Fighters Thrive™
c/o CTCA at Southwestern Regional Medical Center
10109 E. 79th Street
Tulsa, OK 74133
SANCUSO® (Granisetron Transdermal System):
A recommendation from
leading treatment guidelines1,2
When preparing for chemotherapy, be
armed
&
ready
For nausea and vomiting
One patch.
One application.
5 days of coverage.3
Visit www.sancuso.com to learn
more and to download a moneysaving co-pay card.
Please refer to the sunlight warning in
the important safety information below.
Important safety information
SANCUSO® (Granisetron Transdermal System) is indicated for the prevention of nausea and vomiting in patients receiving moderately and/or highly emetogenic
chemotherapy regimens of up to 5 consecutive days duration.4 SANCUSO is contraindicated in patients with known hypersensitivity to granisetron or to any of the
components of the patch.4 Granisetron may mask a progressive ileus and/or gastric distention caused by the underlying condition.4 Mild application site reactions
have occurred; remove the patch if severe reaction or a generalized skin reaction occurs.4 Patients should avoid direct exposure of application site to natural or
artificial sunlight by covering with clothing while wearing the patch and for 10 days after removing it.4 The most common adverse reaction in patients receiving
SANCUSO is constipation (5.4%).4 SANCUSO contains granisetron.4 Healthcare professionals should avoid prescribing any additional products that contain
granisetron. No clinically relevant drug interactions have been reported in clinical studies with SANCUSO.4
References:
1. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Antiemesis. V.1.2012. http://www.nccn.org/
professionals/physician_gls/pdf/antiemesis.pdf. Accessed December 13, 2011. 2. Basch E, Prestrud AA, Hesketh PJ, et al. Antiemetics: American
Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2011;29(31):4189-4198. 3. Boccia RV, Gordan LN, Clark G, Howell
JD, Grunberg SM; on behalf of the Sancuso Study Group. Efficacy and tolerability of transdermal granisetron for the control of chemotherapyinduced nausea and vomiting associated with moderately and highly emetogenic multi-day chemotherapy: a randomized, double-blind, phase III
study. Support Care Cancer. 2011;19(10):1609-1617. 4. SANCUSO [package insert]. Bridgewater, NJ: ProStrakan, Inc; 2011.
ONLY
www.prostrakan-usa.com
www.sancuso.com
SANCUSO is a registered trademark of ProStrakan, Inc.
©2012 ProStrakan, Inc.
All rights reserved. Printed in U.S.A. SAN-2012-006 February 2012
Please see brief summary of
Prescribing Information on adjacent page.
Keeps them covered